145 related articles for article (PubMed ID: 36796466)
1. Covalent targeting the LAS1-NOL9 axis for selective treatment in NPM1 mutant acute myeloid leukemia.
Han Y; Hu A; Qu Y; Xu Q; Wang H; Feng Y; Hu Y; He L; Wu H; Wang X
Pharmacol Res; 2023 Mar; 189():106700. PubMed ID: 36796466
[TBL] [Abstract][Full Text] [Related]
2. Las1 interacts with Grc3 polynucleotide kinase and is required for ribosome synthesis in Saccharomyces cerevisiae.
Castle CD; Sardana R; Dandekar V; Borgianini V; Johnson AW; Denicourt C
Nucleic Acids Res; 2013 Jan; 41(2):1135-50. PubMed ID: 23175604
[TBL] [Abstract][Full Text] [Related]
3. Imidazoquinoxaline derivative EAPB0503: A promising drug targeting mutant nucleophosmin 1 in acute myeloid leukemia.
Nabbouh AI; Hleihel RS; Saliba JL; Karam MM; Hamie MH; Wu HJM; Berthier CP; Tawil NM; Bonnet PA; Deleuze-Masquefa C; El Hajj HA
Cancer; 2017 May; 123(9):1662-1673. PubMed ID: 28055106
[TBL] [Abstract][Full Text] [Related]
4. Grc3 programs the essential endoribonuclease Las1 for specific RNA cleavage.
Pillon MC; Sobhany M; Borgnia MJ; Williams JG; Stanley RE
Proc Natl Acad Sci U S A; 2017 Jul; 114(28):E5530-E5538. PubMed ID: 28652339
[TBL] [Abstract][Full Text] [Related]
5. Heliangin acts as a covalent ligand of RPS2 that disrupts pre-rRNA metabolic processes in
Feng Y; Han Y; Hu A; Qu Y; Hu Y; Wu H; Wang X; He L
Acta Pharm Sin B; 2023 Feb; 13(2):598-617. PubMed ID: 36873185
[TBL] [Abstract][Full Text] [Related]
6. Nol9 is a novel polynucleotide 5'-kinase involved in ribosomal RNA processing.
Heindl K; Martinez J
EMBO J; 2010 Dec; 29(24):4161-71. PubMed ID: 21063389
[TBL] [Abstract][Full Text] [Related]
7. Nucleophosmin 1: from its pathogenic role to a tantalizing therapeutic target in acute myeloid leukemia.
Shi Y; Xue Y; Wang C; Yu L
Hematology; 2022 Dec; 27(1):609-619. PubMed ID: 35621728
[TBL] [Abstract][Full Text] [Related]
8. Nuclease integrated kinase super assemblies (NiKs) and their role in RNA processing.
Pillon MC; Stanley RE
Curr Genet; 2018 Feb; 64(1):183-190. PubMed ID: 28929238
[TBL] [Abstract][Full Text] [Related]
9. Deguelin, a selective silencer of the NPM1 mutant, potentiates apoptosis and induces differentiation in AML cells carrying the NPM1 mutation.
Yi S; Wen L; He J; Wang Y; Zhao F; Zhao J; Zhao Z; Cui G; Chen Y
Ann Hematol; 2015 Feb; 94(2):201-10. PubMed ID: 25242579
[TBL] [Abstract][Full Text] [Related]
10. EAPB0503, an Imidazoquinoxaline Derivative Modulates SENP3/ARF Mediated SUMOylation, and Induces NPM1c Degradation in NPM1 Mutant AML.
Skayneh H; Jishi B; Hleihel R; Hamie M; El Hajj R; Deleuze-Masquefa C; Bonnet PA; El Sabban M; El Hajj H
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408798
[TBL] [Abstract][Full Text] [Related]
11. Mutant NPM1-regulated lncRNA HOTAIRM1 promotes leukemia cell autophagy and proliferation by targeting EGR1 and ULK3.
Jing Y; Jiang X; Lei L; Peng M; Ren J; Xiao Q; Tao Y; Tao Y; Huang J; Wang L; Tang Y; Yang Z; Yang Z; Zhang L
J Exp Clin Cancer Res; 2021 Oct; 40(1):312. PubMed ID: 34615546
[TBL] [Abstract][Full Text] [Related]
12. Nucleophosmin 1 Mutations in Acute Myeloid Leukemia.
Zarka J; Short NJ; Kanagal-Shamanna R; Issa GC
Genes (Basel); 2020 Jun; 11(6):. PubMed ID: 32545659
[TBL] [Abstract][Full Text] [Related]
13. Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML.
Pianigiani G; Gagliardi A; Mezzasoma F; Rocchio F; Tini V; Bigerna B; Sportoletti P; Caruso S; Marra A; Peruzzi S; Petito E; Spinozzi G; Shacham S; Landesman Y; Quintarelli C; Gresele P; Locatelli F; Martelli MP; Falini B; Brunetti L
Blood Adv; 2022 Nov; 6(22):5938-5949. PubMed ID: 36037515
[TBL] [Abstract][Full Text] [Related]
14. When the good go bad: Mutant NPM1 in acute myeloid leukemia.
Kunchala P; Kuravi S; Jensen R; McGuirk J; Balusu R
Blood Rev; 2018 May; 32(3):167-183. PubMed ID: 29157973
[TBL] [Abstract][Full Text] [Related]
15. Current status and future perspectives in targeted therapy of NPM1-mutated AML.
Ranieri R; Pianigiani G; Sciabolacci S; Perriello VM; Marra A; Cardinali V; Pierangeli S; Milano F; Gionfriddo I; Brunetti L; Martelli MP; Falini B
Leukemia; 2022 Oct; 36(10):2351-2367. PubMed ID: 36008542
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the molecular crosstalk within the essential Grc3/Las1 pre-rRNA processing complex.
Pillon MC; Sobhany M; Stanley RE
RNA; 2018 May; 24(5):721-738. PubMed ID: 29440475
[TBL] [Abstract][Full Text] [Related]
17. XPO1 is a new target of homoharringtonine (HHT): Making NPMc
Xue J; Chu P; Gao W; Wang F; Gao Y; Liu S; Kang Z; Yan J; Wang H
Biochem Biophys Res Commun; 2023 Oct; 675():155-161. PubMed ID: 37473530
[TBL] [Abstract][Full Text] [Related]
18. A novel leukemic route of mutant NPM1 through nuclear import of the overexpressed long noncoding RNA LONA.
Gourvest M; De Clara E; Wu HC; Touriol C; Meggetto F; De Thé H; Pyronnet S; Brousset P; Bousquet M
Leukemia; 2021 Oct; 35(10):2784-2798. PubMed ID: 34131282
[TBL] [Abstract][Full Text] [Related]
19. Cytoplasmic Expression of TP53INP2 Modulated by Demethylase FTO and Mutant NPM1 Promotes Autophagy in Leukemia Cells.
Huang J; Sun M; Tao Y; Ren J; Peng M; Jing Y; Xiao Q; Yang J; Lin C; Lei L; Yang Z; Zhang L
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675134
[TBL] [Abstract][Full Text] [Related]
20. Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia.
Kühn MW; Song E; Feng Z; Sinha A; Chen CW; Deshpande AJ; Cusan M; Farnoud N; Mupo A; Grove C; Koche R; Bradner JE; de Stanchina E; Vassiliou GS; Hoshii T; Armstrong SA
Cancer Discov; 2016 Oct; 6(10):1166-1181. PubMed ID: 27535106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
